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Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative brain disorder which is around 1.5
times more common in men than in women. Currently, drug medications, surgery, and lifestyle changes are
common approaches to PD, while all of them focused on reducing the symptoms. Therefore, regenerative medi-
cine based on stem cell (SC) therapies has raised a promising hope. Various types of SCs have been used in
basic and experimental studies relevant to PD, including embryonic pluripotential stem cells, mesenchymal
(MSCs) and induced pluripotent SCs (iPSCs). MSCs have several advantages over other counterparts. They are
easily accessible which can be obtained from various tissues such as bone marrow, adipose tissue, peripheral
blood, etc. with avoiding ethical problems. Therefore, MSCs is attractive clinically because there are no related
ethical and immunological concerns . Further studies are needed to answer some crucial questions about the
different issues in SC therapy. Accordingly, SC-based therapy for PD also needed more complementary evalua-
tion in both basic and clinical study areas.
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Introduction
Parkinson’s disease (PD) is the first or
second most common neurodegenerative
brain disorder after Alzheimer’s disease
that affects the control of body movements
(1, 2). First time PD was formally de-
scribed in "An Essay on the Shaking Pal-
sy," published in 1817 by a London physi-
cian named James Parkinson (3). It is re-
sulted from the degeneration of dopamine-
producing nerve cells in the substanti-
anigra, a region in the mesencephalon that
controls movement. This degeneration re-
sults in a reduction of a neurotransmitter
called dopamine in the brain which is nec-
essary for regulating of body movement.
Clinical signs of PD appear when about
70% of the dopamine-producing neurons
are damaged. Symptoms of PD include
slow physical movements (bradykinesia),
shaking (tremor), muscle stiffness (rigidity)
and postural instability (impaired balance
and coordination), and pain (4-7). PD is
about 1.5 times more common in men than
in women, and its prevalence increases
with age. It affects about 1%–2% of the
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population over 70 years of age (8). The
causes of PD are still unknown, however a
number of researchers believe that it devel-
ops in response to a combination of certain
genetic and non-genetic factors (9).
Current treatments for Parkinson’s dis-
ease
There is currently no cure for PD thus;
several treatments have focused on reliev-
ing the symptoms (10). Accordingly, cur-
rent treatments include the use of oral prep-
arations of L-3,4-dihydroxyphenylalanine
(L-DOPA) and dopamine receptor agonists,
apomorphine in more serious cases, contin-
uous intestinal infusion of L-DOPA, and
deep brain stimulation (DBS) in subthalam-
ic nucleus and globus pallidus by using
surgically implanted electrodes (11). There-
fore, pharmacological treatments are based
on the uptake of levodopa (L-DOPA) and
inhibition of dopamine degrading by using
dopamine agonists and also dopamine de-
grading enzymes inhibitors. Today, dopa-
mine receptor agonists are used as the first
choice to delay the starting of L-DOPA.
Furthermore, they will be useful in ad-
vanced stage of PD as adjunct therapy with
L-DOPA. Their mechanism of action is
stimulation of presynaptic and postsynaptic
dopamine receptors. Levodopa as a known
medication for PD treatment has been used
to relieve the effects of dopamine deficien-
cy. Unfortunately, its therapeutic effect is
reduced after around 3-5 years (8, 12-15).
As well, there are some other medications
that are used for PD for instance; Bromo-
criptine, Pramipexole, Ropinirole, anticho-
linergic medications (e.g., Benztropine),
monoamine oxidase B inhibitors (MAO-B-
I), Amantadine, and DBS which stimulates
the part of brain affected by PD (16, 17).
MAO-B-I can stabilize the dopamine levels
in the synaptic cleft. Selegiline and Rasa-
giline are two irreversible MAO-B inhibi-
tors that catalyse the oxidative deamination
of active amines and cause prolonged do-
pamine activity (18). Also, here are some
other types of Levodopa degradation in-
hibitors such as catechol-O-methyl trans-
ferase (COMT) inhibitors (19). All of these
treatments have some considerable side ef-
fects such as wearing off phenomena, mo-
tor fluctuation, and abnormal movements as
dyskinesia. On the other hand, DBS as a
surgical treatment has some serious limita-
tions. It is costly and generally considered
for late stage disease without dementia.
Furthermore, it can produce cognitive dis-
orders, which may be permanent (8). As
current therapeutic approaches for PD only
provide symptomatic relief with serious
limitations therefore, some alternative
treatments such as regenerative medicine
and stem cells (SCs) therapy are necessary
(20-22). There are several types of (stem)
cells that have been investigated as poten-
tial candidates for cellular therapy in vari-
ous neurological disorders such as spinal
cord injury, multiple sclerosis,  stroke, and
PD, including embryonic pluripotential
SCs, fetal or adult SCs (hematopoietic and
mesenchymal SCs), iPSCs from different
sources, and human fetal ventral mesence-
phalic (hfVM) tissue that contains nigral
dopaminergic cells (23-29). Different types
of stem cells have been investigated for
treatment of PD with specific advantages
and disadvantages (Table 1). The purpose
of this review is to describe various sources
of SCs that are candidate for treatment of
PD.
Embryonic stem cells (ESCs)
These are “pluripotent cells” derived from
the inner cell mass of a blastocyst (2, 32)
and can differentiate into any type of cell in
the body for instance, nigral dopaminergic
neurons (33-35). On the other hand, human
ESCs are a source of dopamine neurons for
transplantation in PD (36, 37). It has been
demonstrated that, embryonic pluripotential
stem cells-derived dopaminergic neurons
generate functional recovery after trans-
plantation into the striatum of PD in animal
models (38). However, there are some seri-
ous concerns about the use of these cells for
treatment of PD or other neurodegenerative
diseases. Tumor formation is one of the
most important adverse effects which can
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be avoided by cell sorting, prolonged dif-
ferentiation and subsequently exhaustion in
vitro before transplantation (11, 39-42).
Several animal studies have shown a mild
to moderate improvement in PD symptoms
after transplantation of ESCs or neural stem
cells differentiated from embryonic plu-
ripotential stem cells (38, 43-45).
Mesenchymal stem cells (MSCs)
MSCs are multipotent cells which can be
commonly isolated from bone marrow.
Bone marrow-derived mesenchymal stem
cells (BMSCs) are the most well studied
MSCs. Additionally, there are some other
MSCs sources, such as umbilical cord,
dermis, adipose tissue, peripheral blood,
etc. (29, 31, 46-48). They have potentially
self–renewal property with differentiation
capacity into a variety of cells such as oste-
oblasts, chondrocytes, myocytes, adipo-
cytes, fibroblasts, neurons, and also dopa-
minergic neurons (48-50). MSCs can pro-
tect injured tissues to generate a wide spec-
trum of cells, for instance, dopamine neu-
rons, which can renew damaged or lost
cells in PD (31, 51, 52). Although, it has
been demonstrated that embryonic pluripo-
tential stem cells and neural stem cells
(NSCs) are considerable candidates for
transplantation therapy in neurodegenera-
tive diseases (53), there are some limita-
tions on using of them such as potential
problems of cell regulation, ethical issues,
and probability of tumorigenicity. Accord-
ingly, several studies showed that MSCs
have a high therapeutic potential against
neurological diseases, without the men-
tioned limitations. In addition, MSCs are
readily accessible, isolated and expanded
easily with no risk of rejection (54). MSCs
have low immunogenic properties due to
the lack of MHC-II (55). Furthermore, they
have protective effects on dopaminergic
neurons loss in animal models and human
(56-64). Some experimental studies eluci-
dated that MSCs are potentially useful as
vectors for treating a variety of central
nervous system disorders (65). These find-
ings also revealed MSCs ability to trans-
differentiate into special neurons which is a
substantial factor for treating neurodegen-
erative disorders. Some clinical transplanta-
tion trials are performed by using MSCs for
treatment of PD. For instance, autologous
BMSCs were used in a clinical trial in
which patients followed for up to 36
months after transplantation. This trial
Table 1. Advantages and disadvantages of stem cell types used in Parkinson’s disease (11, 26, 30, 31)
Type of stem cell Advantages Disadvantages
Embryonic stem cell
(ESCs)
(a) Highly proliferative/pluripotent
(b) Able to form all three germ layer
(c) Generate dopaminergic neurons
(d) Transplantation survival/some degree of functional
recovery
(a) Risk of tumor formation
(b) Ethical issues
(c) Genomic instability
Induced pluripotent
stem cells (iPSCs)
(a) Unlimited PD patient-specific cells/autologous
transplantation
(b) Transplantation survival/some degree of functional
recovery
(c) Minimized immune reactions and ethical issues
(a) Risk of tumor formation
(b) In autologous transplantation risk
of susceptibility to the
original pathology of the patient
Mesenchymal stem
cells (MSCs)
(a) Improve motor performance in mice
(b) No reported adverse effects in humans
(c) A realistic cell source for regenerative medicine
(d) Easily accessible from different tissues
(a) Modest clinical improvement
in humans
Fetal brain neural
stem cells (fNSCs)
(a) Lower risk of tumor formation and immune
rejection in comparison with ESCs
(b) Ability to differentiate into neurons, astrocytes,
oligodendrocytes, and dopamine neurons
(a) Limited differentiation in vivo
(b) Partial effect in PD-like symp-
toms
(C) Risk of GIDs
(d) Ethical issues
(e) Histocompatibility concerns (f)
limited supply
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showed partial improvement with no tumor
formation or other side effects. Although
MSCs have been promising candidate for
treatment of PD, more clinical studies are
needed regarding MSC transplantation and
its safety and efficacy (31).
Induced pluripotent stem cells (iPSCs)
iPSCs are usually derived from adult so-
matic cells, such as fibroblasts by overex-
pressing self-renewal and pluripotency fac-
tors (Oct4, Sox2, Klf4, and Myc) (66, 67).
Besides pluripotency and self-renewal
properties, iPSCs have some advantages as
a source for cell-replacement therapies. For
instance, the opportunity to obtain the re-
programmed cells directly from the pa-
tients, thus potentially reducing the risk of
transmissible infections and immune reac-
tions following cellular therapy (68). Ra-
ther, using iPSCs in basic and clinical re-
searches has no ethical limitations. In other
words, for treatment of PD, patients own
somatic cells can be differentiated into a
pluripotent state to produce dopaminergic
neurons which could be transplanted into
the patient’s brain (69, 70). iPSCs are coun-
terparts of embryonic pluripotential stem
cells in morphology, proliferation, surface
antigens, and ability to differentiate into
three germ layer cells (71). Several basic
and clinical investigations elucidated prom-
ising role of iPSCs in regenerating dopa-
minergic neurons as the underlying factor
in treatment of PD. Transplantation of these
cells into the striatum ameliorated PD
symptoms (10, 11, 31, 72, 73). Although,
the use of iPSCs has various advantages,
the risk for tumor formation is a serious
obstacle to use these cells in clinical trans-
plantation trials. Accordingly, it is needed
to minimize this risk and the probability of
genetic mutations before translating iPSCs
related basic science into clinical setting in
PD (11, 74, 75).
Other tissue sources
Different tissues were used for treatment
of PD including; carotid body, sympathetic
ganglion neurons, and adrenal medulla. Ca-
rotid body is located in the bifurcation of
common carotid artery and has some do-
paminergic cells as an alternative treatment
in PD (76-78). Likewise, sympathetic gan-
glion tissue from cervical and thoracic
sympathetic trunk can be implanted into the
striatum in PD (79). In addition, adrenal
medullary tissue as a source of dopaminer-
gic neurons is another choice for treatment
of PD with limited benefits (80).
Conclusion
Current treatments and medications of PD
try to relieve motor symptoms by providing
dopamine substitutes or dopamine receptors
agonists and also in advanced PD patients,
apomorphine, continuous intestinal admin-
istration of L-Dopa, and DBS (19, 81). Alt-
hough these treatments have some effects
on controlling symptoms, their adverse ef-
fects are considerable. Additionally, they
cannot replace or regenerate the lost dopa-
minergic neurons. While, cellular therapy
using stem cells extracted from different
sources such as, hfVM tissue can provide
dopaminergic neurons regeneration, re-
placement, and reinnervation and also
symptomatic relief lasting for several years
following transplantation in some cases that
were able to withdraw from L-DOPA ther-
apy (11, 18, 19, 26, 82). Therefore, it is the
time to apply a novel and more effective
treatment for PD by cellular therapy and
regenerative medicine. Nowadays, stem
cell therapy has turned into an attractive
field of science for researchers and conse-
quently stem cells have been optimized to
use for treatment of various neurological
disorders based on their potential to differ-
entiate into neural cells. In particular, these
cells could be induced to generate dopa-
minergic neurons for an effective treatment
of PD (31). Although, there are no good-
established inclusion criteria for patient se-
lection, several clinical trials have intro-
duced criteria to include the PD patients in
their trials (83). For instance, some studies
have included patients with at least 2 fea-
tures of PD (tremor, rigidity, or bradykine-
sia), good response to L-dopa, and intact
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higher mental functions (84) and also a
minimum of 7 years of treatment, the pres-
ence of intractable problems (more ad-
vanced stages), taking L-dopa for several
years and established L-dopa induced dys-
kinesia (8). In addition, more precise inclu-
sion criteria have been introduced in some
ongoing clinical trials. For instance, a clini-
cal trial has described the inclusion criteria
as below;
- Males and females aged 18-80 years.
- Current diagnosis of PD with motor
complications according to standard crite-
ria.
- Responsiveness to dopa agonists.
- Stage 2.5, 3 & 4 based-on HOEHN &
YAHR staging.
- Stable medications for 60 days prior to
the surgery.
- No gross atrophy or any other patholo-
gy of brain in MRI.
- Montgomery-Asberg Rating Scale
(MADRS) less than 19 for depression.
- No significant cognitive impairment
(MMSE > 21) (85).
Obviously, better realizing the underlying
basic and cellular mechanisms of PD could
help scientists to explicate safe and effi-
cient stem cell-based approaches to over-
come side effects such as uncontrolled dif-
ferentiation and growth which can induce
tumor formation. Although, it is elucidated
that dopaminergic neurons generated from
stem cells can be the best candidate for
treatment of PD, It is needed to understand
more about the basic etiology of PD, also
dopaminergic cell differentiation, regenera-
tion, and function. MSCs have several ad-
vantages over embryonic pluripotential
stem cells. iPSCs, and neural stem cells, for
example, they can be obtained from pa-
tients for auto even allo-transplantation
(31). Moreover, MSCs are easily accessible
that can be obtained from different types of
tissues such as bone marrow, adipose tis-
sue, peripheral blood, etc. with no ethical
problems (86). Accordingly, it seems that
MSCs are the ideal candidate and maybe
ready to translate from the basic and exper-
imental researches to the clinical transplan-
tation trials in various diseases including,
neurological disorders and PD. On the oth-
er hand, embryonic pluripotential stem
cells, iPSCs, and also fetal stem cells have
some valuable properties in comparison
with adult MSCs for instance, pluripotency
and self-renewal capacity, which introduce
them as a considerable source for research
and future cellular therapies. Of course,
various ethical problems and safety con-
cerns (e.g. tumorigenesis), are needed to
overcome by performing further investiga-
tions in both fields (11). Generally, against
the promising clinical potential of (stem)
cell based therapies, there are also potential
risks. Some of the considerable risks of
stem cell based therapies include; 1) trans-
plantation site reactions, 2) immune re-
sponse to the transplanted cells, 3) biodis-
tribution/ectopic grafting, 4) unintended
differentiation into another cell type, 5) tu-
morigenicity, and 6) lack of functional
characteristics (30). As it has been de-
scribed, there are various cell or stem cell
sources that have been used for treatment
of PD, but the most successful clinical trials
have applied hfVM tissue to treat PD (26).
Therefore, we are trying to explain more
details of the characteristics, complications,
and different aspects of this treatment in
comparison with other types of cellular
therapies. Following implantation of hfVM
tissue, survival of grafted dopaminergic
neurons, has been shown in the PD pa-
tients’ brain striatum using positron emis-
sion tomography (PET), and histopatholog-
ical methods (86, 87). Dopaminergic grafts
can be functionally integrated into neural
circuitries in brain (87). Additionally, it has
been demonstrated that, afferent and effer-
ent synaptic connections can be established
between grafted and host neurons. Long-
term survival of the implanted grafts have
been reported several years (more than 10
years) after transplantation (86,88) with
acceptable function and restoring dopamine
release in the PD patient’s brain (87). Al-
ternatively, following stem cell transplanta-
tion, dopamine restoring could be provided
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by two different paths; 1) in vitro pre-
differentiation of stem cells toward dopa-
minergic neurons prior to transplantation,
2) In vivo differentiation toward dopamin-
ergic neurons after implantation into the PD
patient’s brain (86). Consequently, HfVM
tissue transplantation has some complica-
tions such as producing Lewy bodies after
transplantation and graft-induced dyskine-
sias (GID) (26, 87). Furthermore, there
were lack of homogeneity of effects in ini-
tial clinical trials and also they caused GID
as a considerable adverse event in a sub-
group of patients (11). Accordingly, the
most serious complication after hfVM tis-
sue transplantation is GIDs which can be
treated with DBS in the globus pallidus
(87). Various studies showed that GIDs are
caused by the hfVM graft-derived sero-
tonergic hyperinnervation. These investiga-
tions supported some evidence-based strat-
egies for avoiding GIDs following treat-
ment of PD using hfVM tissue or stem
cells. As the hfVM tissue contains both do-
paminergic and serotonergic cells, thus
minimizing the serotonergic portion of the
graft is seriously suggested to reduce occur-
rence of GIDs. On the other hand, during
processing and preparation of dopaminergic
neurons from different sources of stem
cells, depletion of serotonergic neurons
should be considered as a rule. In addition,
stem cell expansion and long-term storage
of the grafts before transplantation could
reduce the dopaminergic/non-dopaminergic
ratio, thus avoiding cell manipulation or
long term storage, could help investigators
to decrease the incidence of GIDs. An al-
ternative treatment of GIDs is the systemic
administration of serotonin 1A agonists,
which can reduce transmitter release from
serotonergic neurons (11,87). It also should
be noted that, non-motor symptoms such as
dementia is not effectively treated by using
current medications and DBS (87). Like-
wise, some patients who received the do-
paminergic grafts still suffered from
nonmotor symptoms including depression,
dementia, visual hallucinations, and sleep
disorders. Therefore, cellular therapy for
PD needs additional transplantation of sero-
tonergic neurons to relieve nonmotor symp-
toms (88). There are various trials that have
been performed in the mentioned arena us-
ing stem cells or hfVM tissue grafts. In
some of them the grafts or cells have been
implanted unilaterally (84) and in others
bilaterally (83, 86, 88, 89) in different parts
of the brain such as putamen (86, 88, 89),
sublateral ventricular zone (83, 84), and
caudate nucleus (88). Additionally, in these
trials, the number of transplanted stem cells
was 1-2 million cells/Kg of body weight
(83,88). Eventually, results of experimental
studies suggest future (stem) cell-based ap-
proaches to PD, while there are remained
several fundamental questions about the
stem cells’ mechanism of action, adverse
effects, the best cell source for dopaminer-
gic neurons, as well ethical and safety con-
cerns particularly about embryonic pluripo-
tential stem cells and iPSCs (11, 86).
Therefore, stem cell-based therapies for PD
are still in its infancy and performing more
experimental researches as well clinical
trials is crucial for advancement of
knowledge in this arena (86).
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